Kuchyne na miru

Noteworthy

Mar 21, 2019
Pharmaceutical Executive
Perspectives from big pharma and the rare disease space on how patient advocacy is evolving as a corporate function.
Mar 20, 2019
By
Clinical trials for precision therapies will require a healthy dose of education, collaboration, and data-driven decision-making—not to mention a dedication to digital technology, says Justin Grossman.
Mar 20, 2019
Pharmaceutical Executive
Eli Lilly's Michael W. Magdycz discusses the ways in which country-level leaders approach governance and decision-making.
Mar 07, 2019
Pharmaceutical Executive
Wide-ranging probes to target marketing, pricing, and access. Jill Wechsler reports.
Mar 07, 2019
Pharmaceutical Executive
Despite a “temporary fix” at the ready, pharma supply repercussions loom if exit deal isn’t reached this month.
Mar 06, 2019
Pharmaceutical Executive
By
An industry working group has developed a common framework focused on the most relevant access performance metrics (APMs).
Mar 05, 2019
If payers are the fastest growing influencers in healthcare (and they are), why is it that payer-targeted advertising campaigns are often an afterthought? Amber Gilbert reports.
Feb 28, 2019
Applying game mechanics to healthcare marketing efforts has significant potential to ensure that patients are activated, educated and engaged throughout the duration of their care.
Feb 11, 2019
In preparing to launch a rare-disease medication, it is important to understand the needs in the therapy area and invest strategically to maximize the impact on the unique rare-disease environment.
Feb 11, 2019
Stefan Spazek outlines the steps for biopharma startups in tapping non-dilutive financing options.
native1_300x100
https://gas-energy.com.ua

website development

гранитная плитка цена
lorem ipsum